Conference Coverage

Reports from professional meetings related to Hodgkin lymphoma.
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD)
Presenter: M. Albitar Presenter's Affiliation: MD Anderson Cancer Center, Texas Type of Session: Scientific Background CD20 is a Glycoprotein transmembrane receptor found on mature B-cells. Differences in the levels of ..
Single Dose Pegfilgrastin (SD/01) Is as Effective as Daily Filgrastim Following ESHAP Chemotherapy for Subjects wtih Non-Hodgkin's Lymphoma or Hodgkin's Disease: Results of a Randomized, Open-Label Study
Presenter: Julie M. Vose Presenter's Affiliation: University of Nebraska Medical Center, Omaha, NE Type of Session: Scientific Background Pegfilgrastim is a pegylated form of filgrastim that has previously been shown ..
Two Cycles ABVD Plus Extended Field Radiotherapy Is Superior to Radiotherapy Alone in Early Stage Hodgkin's Disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7
Presenter: Markus SieberPresenter's Affiliation: University of CologneType of Session: ScientificBackground Extended Field (EF)Radiotherapy alone has been considered the standard for early stage Hodgkin's Disease (HD) with 90% 10 year Overall ..
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's Lymphoma.  Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG)
Presenter: V. DiehlPresenter's Affiliation: German Hodgkin's Study GroupType of Session: ScientificBackground Patients with early stage Hodgkin's lymphoma (HL) have an excellent prognosis This is especially true in patients without risk ..
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
Presenter: R.P. MullerPresenter's Affiliation: Medical University of Vienna, AustriaType of Session: PlenaryBackground Combined modality treatment consisting of few cycles of chemotherapy, usually ABVD, followed by involved field radiotherapy is the ..
ASTRO Patient Summary: Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
This study looked at patients with early stage (I and II) Hodgkin's disease. There is some controversy over the dose of radiation therapy and the number of cycles of standard ..
Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) Randomized HD11 Trial
Authors: H. T. Eich, R. P. Mueller, V. Diehl, H. Gorgen, H. Mueller-Hermelink, B. Schmidt, Grosu, J. Karstens, N. Willich, A. Engert Institutions: Department of Radiation Oncology, University of Cologne, ..
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
Authors: R. P. Mueller, H. T. Eich, A. Plutschow, J. Debus, M. Bamberg, K. Wilborn, M. Eble, H. Muller-Hermelink, V. Diehl, A. Engert Institutions: Radioonkologie, Klinikum der Universitaet zu Koeln, ..
Hodgkin Lymphoma: Cardiovascular Diseases after Hodgkin Lymphoma Treatment: 35-year Disease Risk and Sequence of Events
Presenting Author: Berthe Aleman Presenting Author Affiliation: The Netherlands Cancer Institute The treatment of Hodgkin Lymphoma has transformed over the last 35 years. While curative treatments have been available for ..
Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
Presenter: Sai Ravi Pingali, MD Presenter's Affiliation: Medical College of Wisconsin Affiliated Hospitals, Milwaukee, Wisconsin Abstract #: 8505 Background Hodgkin lymphoma is a fairly uncommon cancer, with ~8,000 cases diagnosed ..
Consolidative Proton Therapy in Patients with Hodgkin Lymphoma: Early Outcomes
Presenting Author: Bradford Hoppe, MD Presenting Author Affiliation: University of Florida Proton Therapy Institute, Radiation Oncology, JacksonvilleBackground There are approximately 9000 cases of Hodgkin lymphoma diagnosed annually in the United ..
Dose to Abdominal Organs with Proton Therapy in Diaphragmatic and Infradiaphragmatic Hodgkin Lymphoma
Presenter: Bradford Hoppe, MD Presenter's Affiliation: University of Florida Background Hodgkin Lymphoma typically occurs in young patients age 15-40 years old. Treatment usually involves chemotherapy followed by consolidative radiation therapy. ..
Involved-Field Radiotherapy in Patients with Stage III/IV Hodgkin's Lymphoma: First Results of the Randomized EORTC Trial # 20884
Presenter: B.M. Aleman Presenter's Affiliation: EORTC Lymphoma Group, Brussels, Belgium Type of Session: Plenary Background While the role of radiation therapy in the treatment of early stage Hodgkins Disease is ..
Alternative Targets for Immunotherapy: Targeting CD22 With Monoclonal Antibodies for the Treatment of Non-Hodgkin?s Lymphoma
Presenter: John P. Leonard, MD Affiliation: Cornell University While mortality rates for patients with prostate cancer or breast cancer are decreasing, death rates for patients with non-Hodgkin?s lymphoma continue to ..
Study of Bone Marrow Involvement in 1161 Consecutive Hodgkin's Lymphoma Patients.
Presenter: Alessandro Lewis Affiliation: Piemonte Hodgkin's Disease Registry. Alessandria, Italy Background In Hodgkin's Disease(HD) bone marrow involvement(BMI) has been reported as a unfavorable prognostic factor. Accordingly, bone marrow biopsy(BMB) is ..
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Michael G. Pfreundlschuh Presenter's Affiliation: Type of Session: Scientific Background Low Risk (normal LDH)aggressive NHL has classically been treated with CHOP chemotherapy given on a 21 day dosing schedule. ..
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.
Presenter: David Eilender Presenter's Affiliation: Wayne State University Type of Session: Poster Background Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL). It ..
CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial
Presenter: T.P. Miller Presenter's Affiliation: Arizona Cancer Center, Tuscon, AZ Type of Session: Scientific Background In 1998, SWOG study 87-36 reported the results of a randomized trial comparing 8 cycles ..
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Karoline Spaepen Affiliation: Leuven, Belgium Background Positron Emission Tomography (PET) with FDG (a radiolabeled sugar molecule) is a nuclear medicine study that is able to detect areas of active ..
Fludarabine Compared with CVP Chemotherapy in Newly diagnosed Patients with Stages III and IV Low Grade Malignant Non-Hodgkin?s Lymphoma. Final Analysis of a Prospective Randomized Phase III Intergroup Study in 381 Patients
Presenter: A. Hagenbeek Presenter's Affiliation: Type of Session: Scientific Background In 1993, the EORTC lymphoma group initiated a prospective randomized trial in newly diagnosed, low grade non-Hodgkin?s lymphoma (NHL) patients ..
Advances in Non-Hodgkin's Lymphoma (NHL) Treatment
Conference Dates: September 10, 2004 Conference Location: Audioconference Sponsoring Group: National Marrow Donor Program, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research Conference Web Page ..
Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL)
Presenter: Emma MorrisPresenter's Affiliation: UK Collaborative Group, United KingdomType of Session: ScientificBackground Campath is an antibody that targets CD 52 which is a T cell marker. Campath has been studied ..
Radiotherapy is Unnecessary in Elderly Patients With Localized Aggressive Non-Hodgkin's Lymphoma: Results of the GELA LNH 93-4 Study
Presenter: Georges FilletPresenter's Affiliation: Hematology, CHU - Sart TilmanType of Session: ScientificBackground CHOP plus local radiotherapy is considered the standard treatment for localized, aggressive Non-Hodgkin's Lymphoma (NHL). It has been ..
FDG-PET Is Superior to Gallium Scintigraphy in the Staging and Follow-Up of Patients with De Novo Hodgkin's Disease: a Prospective, Blinded Comparison
Presenter: Jonathan W. FriedbergPresenter's Affiliation: University of RochesterType of Session: PosterBackground Accurate hodgkin's disease (HD) staging with CT scan and nuclear scintigraphy allows optimal treatment planning and prevents under or ..
Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma
Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground Virtually all patients with low Grade Non-Hodgkin's Lymphoma (LG NHL) relapse. Relapsed or refractory LG NHL is very difficult ..
Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL)
Presenter: J.M. VosePresenter's Affiliation: University of Nebraska Medical CenterType of Session: PosterBackground Standard therapy for NHL is combination chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) Rituxan, a mouse/human anti CD 20 antibody has ..
Non-Myeloablative Radio-Immunotherapy With a Iodine-131-Tagged Anti-CD30 Antibody (131I-Ki-4) in Patients With Refractory Hodgkin's Lymphoma
Presenter: Roland SchnellPresenter's Affiliation: University of CologneType of Session: ScientificBackground Relapsed Hodgkin's Disease (HD) has a poor prognosis. More treatment alternatives are neeeded. HD is a good target for immunotherapy ..
Patient-specific therapeutic vaccines for non-Hodgkin's lymphoma
Faculty Disclosure: John M. Timmerman, M.D. The presentation by Dr Timmerman includes discussion of vaccine therapy that has not been approved by the FDA and the use of GM-CSF as ..
Modulating IL-2 for Non-Hodgkins' Lymphoma (NHL)
Faculty Disclosure: Michael A. Caligiuri, M.D. This presentation by Dr. Caligiuri discusses off-label use of IL-2 for the treatment of NHL. Presenter: Michael A. Caligiuri, M.D. Affiliation: James Cancer Hospital ..
ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma.  Final results of the IIL HD9601 randomized trial
Presenter: M. FedericoPresenter's Affiliation: Intergruppo Italiano LinfomiType of Session: ScientificBackground The standard treatment for advanced Hodgkin's lymphoma (HL) is ABVD chemotherapy 30% of patients with advanced HL do not respond ..
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of ..
The German Multinational GPOH-HD 95 Trial: Treatment Results and Analysis of Failures in Pediatric Hodgkins Disease Using Combination Chemotherapy With and Without Radiation
Presenter: Ruhl, UrsulaPresenter's Affiliation: Radiation Oncology, Moabit Hospital, Berlin, GermanyType of Session: PlenaryBackground Treatment results of pediatric Hodgkin's disease are excellent now and are difficult to improve with respect to ..
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD11 trial of the GHSG
Presenter: B.C. KlimmPresenter's Affiliation: German Hodgkin's Study Group (GHSG)Type of Session: ScientificBackground - Combined modality therapy with 4-6 cycles ABVD and Involved Field Radiation (IFRT) is the standard of care ..
First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable of unfavorable early stage Hodgkin's lymphoma (HL)
Presenter: E.M. NoordijkPresenter's Affiliation: EORTCType of Session: ScientificBackground Hodgkin's lymphoma (HL) has an excellent prognosis, yet optimal therapy has still yet to be found Patients are treated based on known ..
Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16-21years of age with Hodgkin's disease (HD): The Children's Cancer Group (CCG) experience
Presenter: J. NachmanPresenter's Affiliation: Children's Hospital, Redmond, WAType of Session: ScientificBackground Little data exist regarding treatment outcomes in HD patients aged 16-21 years.  The optimal combination of chemotherapy with or ..
Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD)
Presenter: Andrea NgPresenter's Affiliation: Brigham and Women's Hospital, Boston, MAType of Session: ScientificBackground The historical approach to the management of early stage Hodgkin's disease was radiation alone. Recently, the standard ..
Volume of Abnormal Tumor Tissue on FDG-PET -A Predictor of Progression-free Survival in Hodgkin's Lymphoma?
Presenter: Martin HutchingsPresenter's Affiliation: Copenhagen University Hosptial, Copenhagen, DenmarkType of Session: ScientificBackground Pre-treatment tumor volume is a well characterized independent risk factor for developing tumor recurrence in Hodgkin's Lymphoma. PET ..
ASTRO Patient Summary: Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD)
Long-Term Results of a Prospective Trial of Mantle Irradiation (RT) Alone for Early-Stage Hodgkin's Disease (HD) Historically, patients with early stage Hodgkin's Disease were treated with radiation therapy alone. More ..
Motexafin Gadolinium (MGd): Targeting Oxidative Stress Pathways for the Treatment of Non-Hodgkin's Lymphoma
Presenter: Andrew M. Evans, DO, MSCIPresenter's Affiliation: Northwestern University, Chicago, IllinoisType of Session: ScientificBackground Motexafin Gadolinium (MGd or Xcytrin) is a novel anti-cancer agent which disrupts redox- dependent pathways by ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Presenter: Milone, G.Presenter's Affiliation: Instituto de Investigaciones Hematologicas, Buenos Aires, ArgentinaType of Session: ScientificBackground Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated ..
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group
Presenter: Cacchione, RPresenter's Affiliation: CEMIC ArgentinaType of Session: ScientificBackground Non-Hodgkin’s Lymphoma (NHL) represents a diverse group of malignancies and has a variable presentation, ranging from indolent to aggressive.  Diffuse large ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with chemotherapy as well as immunotherapy with or without linked radionuclides. Fludarabine (F) ..
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group
The purpose of this prospective study was to address the efficacy of Yttrium ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory lymphomas who had already failed rituximab. Rituximab is ..
Breast Cancer After Supradiaphragmatic Irradiation for Hodgkin's Disease; Risk Analysis and Possible Surveillance Strategies
Presenter: M. A. Alm El-Dina, MDPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Radiation therapy imparts an antitumor effect through the formation of free radiations. Radiation can also have effects on ..
Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy
Title: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy Reviewer: Arpi Thukral, MD Presenter: M. M. O'Brien Affiliation: Stanford University There ..
Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study
Presenter: M. T. Milano, Department of Radiation Oncology, University of Rochester, Rochester, NY Background Second malignant neoplasms are the leading cause of death among long-term survivors of Hodgkin lymphoma (HL) ..
Predictors of early response and event-free survival in Hodgkin lymphoma (HL):PET versus CT imaging
Presenter: C. L. Schwartz Presenter's Institution: Hasbro Children's Hospital/Brown University Introduction/Background Response directed therapy is an important concept in the management of Hodgkin Lymphoma (HL). In adult HL, risk stratification ..
Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response
Presenter: Monika Metzger, MD Presenter's Affiliation: St. Jude Children's Research Hospital Background Low-risk Hodgkin lymphoma typically refers to stage I-IIA, non-bulky disease in less than 3 sites, and without extranodal ..
Patterns of Relapse From a Phase III Study of Response-based Therapy for Intermediate-risk Hodgkin Lymphoma (AHOD0031): A Report from the Children’s Oncology Group
Abstract # 12 Presenter: KV.V. Dharmarajan Presenter's Affiliation: Memorial Sloan Kettering Cancer Center Background Hodgkin’s lymphoma constitutes about 6% of childhood cancers and is most common in children > 10 ..
Second Cancer Risk 40 Years After Hodgkin Lymphoma Treatment
Presenter: Berthe Aleman, MD, PhD Affiliation: The Netherlands Cancer Institute Background Large studies have identified increased risk of breast and other cancers in survivors of Hodgkin lymphoma, partially due to ..
Proton Therapy in the Management of Non-Hodgkin Lymphoma
Presenter: Bradford Hoppe, MD Presenter's Affiliation: University of Florida Background Non-Hodgkin Lymphoma is a heterogeneous disease with 66,000 new cases each year The disease involves different lymphoid regions of the ..
Hodgkin Lymphoma: Early Stage Hodgkin Disease Utilization of RT and its impact on OS
Presenting Author: Rahul R. Parikh, MD Presenting Author Affiliation: Mt. Sinai Hospital Cancer patients seek physicians that will provide them with the best available treatment options, especially options with a ..
Hodgkin Lymphoma: Improvements in Treatments for Hodgkin Lymphoma Over a 50-Year Period Lead to Fewer Second Malignancies
Presenting Author: Bouthaina Dabaja Presenting Author Affiliation: MD Anderson Cancer Center After receiving a life-saving cancer treatment, the possibility of being diagnosed with a second, new cancer in the years ..

ASH: Hodgkin's Lymphoma Tx Shows Promise in Small Trial

Dec 9, 2014 - In a small new trial, a form of treatment based on the body's immune system appears to be helping patients with Hodgkin's lymphoma for whom other treatments have failed. The study was published online Dec. 6 in the New England Journal of Medicine to coincide with its expected presentation on Saturday at the annual meeting of the American Society of Hematology, held from Dec. 6 to 9 in San Francisco.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More

OncoLink Cancer Treatment and Resources